• Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine 

      Daniel E Neafsey, Michal Juraska, Trevor Bedford, David Benkeser, Clarissa Valim, Allison Griggs, Marc Lievens, Salim Abdulla, Samuel Adjei, Tsiri Agbenyega, Selidji T Agnandji, Pedro Aide, Scott Anderson, Daniel Ansong, John J Aponte, Kwaku Poku Asante, Philip Bejon, Ashley J Birkett, Myriam Bruls, Kristen M Connolly, Umberto D’Alessandro, Carlota Dobaño, Samwel Gesase, Brian Greenwood, Jonna Grimsby, Halidou Tinto, Mary J Hamel, Irving Hoffman, Portia Kamthunzi, Simon Kariuki, Peter G Kremsner, Amanda Leach, Bertrand Lell, Niall J Lennon, John Lusingu, Kevin Marsh, Francis Martinson, Jackson T Molel, Eli L Moss, Patricia Njuguna, Christian F Ockenhouse, Bernhards Ragama Ogutu, Walter Otieno, Lucas Otieno, Kephas Otieno, Seth Owusu-Agyei, Daniel J Park, Karell Pellé, Dana Robbins, Carsten Russ, Elizabeth M Ryan, Jahit Sacarlal, Brian Sogoloff, Hermann Sorgho, Marcel Tanner, Thor Theander, Innocent Valea, Sarah K Volkman, Qing Yu, Didier Lapierre, Bruce W Birren, Peter B Gilbert, Dyann F Wirth (Massachusetts Medical Society, 2015)
      BACKGROUND The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falciparum and has partial protective efficacy against clinical and severe malaria disease in infants and children. We investigated ...